Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory LymphomaJennifer R. Brown, Farrukh T. Awan, Siddha Kasar et al.|Clinical Cancer Research|2015Cited by 55
Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and LymphomaJennifer R. Brown, Farrukh T. Awan, Matthew S. Davids et al.|Blood|2011Cited by 11